Literature DB >> 25681080

Geographical and Ethnic Distribution of Mutations of the Fumarylacetoacetate Hydrolase Gene in Hereditary Tyrosinemia Type 1.

Francesca Angileri1, Anne Bergeron, Geneviève Morrow, Francine Lettre, George Gray, Tim Hutchin, Sarah Ball, Robert M Tanguay.   

Abstract

Hereditary tyrosinemia type 1 (HT1) (OMIM 276700) is a severe inherited metabolic disease affecting mainly hepatic and renal functions that leads to a fatal outcome if untreated. HT1 results from a deficiency of the last enzyme of tyrosine catabolism, fumarylacetoacetate hydrolase (FAH). Biochemical findings include elevated succinylacetone in blood and urine; elevated plasma concentrations of tyrosine, methionine and phenylalanine; and elevated tyrosine metabolites in urine. The HT1 frequency worldwide is about 1 in 100,000 individuals. In some areas, where the incidence of HT1 is noticeably higher, prevalence of characteristic mutations has been reported, and the estimated incidence of carriers of a specific mutation can be as high as 1 out of 14 adults. Because the global occurrence of HT1 is relatively low, a considerable number of cases may go unrecognized, underlining the importance to establish efficient prenatal and carrier testing to facilitate an early detection of the disease. Here we describe the 95 mutations reported so far in HT1 with special emphasis on their geographical and ethnic distributions. Such information should enable the establishment of a preferential screening process for mutations most predominant in a given region or ethnic group.

Entities:  

Year:  2015        PMID: 25681080      PMCID: PMC4501228          DOI: 10.1007/8904_2014_363

Source DB:  PubMed          Journal:  JIMD Rep        ISSN: 2192-8304


  70 in total

1.  Mutation analysis of the FAH gene in Israeli patients with tyrosinemia type I.

Authors:  Orly N Elpeleg; Avraham Shaag; Elizabeth Holme; Ghaleb Zughayar; Suzi Ronen; Drora Fisher; Haggit Hurvitz
Journal:  Hum Mutat       Date:  2002-01       Impact factor: 4.878

2.  Identification of mutations causing hereditary tyrosinemia type I in patients of Middle Eastern origin.

Authors:  Faiqa Imtiaz; Mohamed S Rashed; Bashayer Al-Mubarak; Rabab Allam; Hanaa El-Karaksy; Zuhair Al-Hassnan; Mohammed Al-Owain; Hamad Al-Zaidan; Zuhair Rahbeeni; Alya Qari; Brian F Meyer; Moeen Al-Sayed
Journal:  Mol Genet Metab       Date:  2011-06-30       Impact factor: 4.797

3.  Hepatocellular carcinoma despite long-term survival in chronic tyrosinaemia I.

Authors:  S Z Kim; K G Kupke; L Ierardi-Curto; E Holme; J Greter; R M Tanguay; J Poudrier; M D'Astous; F Lettre; S H Hahn; H L Levy
Journal:  J Inherit Metab Dis       Date:  2000-12       Impact factor: 4.982

4.  Tyrosinaemia type I--de novo mutation in liver tissue suppressing an inborn splicing defect.

Authors:  Y T Bliksrud; E Brodtkorb; P A Andresen; I E T van den Berg; E A Kvittingen
Journal:  J Mol Med (Berl)       Date:  2005-03-10       Impact factor: 4.599

5.  Identification of a frequent pseudodeficiency mutation in the fumarylacetoacetase gene, with implications for diagnosis of tyrosinemia type I.

Authors:  H Rootwelt; E Brodtkorb; E A Kvittingen
Journal:  Am J Hum Genet       Date:  1994-12       Impact factor: 11.025

6.  On the enzymic defects in hereditary tyrosinemia.

Authors:  B Lindblad; S Lindstedt; G Steen
Journal:  Proc Natl Acad Sci U S A       Date:  1977-10       Impact factor: 11.205

7.  Genetic epidemiology of hereditary tyrosinemia in Quebec and in Saguenay-Lac-St-Jean.

Authors:  M De Braekeleer; J Larochelle
Journal:  Am J Hum Genet       Date:  1990-08       Impact factor: 11.025

8.  Different molecular basis for fumarylacetoacetate hydrolase deficiency in the two clinical forms of hereditary tyrosinemia (type I).

Authors:  R M Tanguay; J P Valet; A Lescault; J L Duband; C Laberge; F Lettre; M Plante
Journal:  Am J Hum Genet       Date:  1990-08       Impact factor: 11.025

9.  A novel mutation causing mild, atypical fumarylacetoacetase deficiency (Tyrosinemia type I): a case report.

Authors:  David Cassiman; Renate Zeevaert; Elisabeth Holme; Eli-Anne Kvittingen; Jaak Jaeken
Journal:  Orphanet J Rare Dis       Date:  2009-12-15       Impact factor: 4.123

10.  Clinical and para clinical findings in the children with tyrosinemia referring for liver transplantation.

Authors:  Seyed Mohsen Dehghani; Mahmood Haghighat; Mohammad Hadi Imanieh; Hossein Karamnejad; Abdorrasoul Malekpour
Journal:  Int J Prev Med       Date:  2013-12
View more
  21 in total

1.  Tissue-specific FAH deficiency alters sleep-wake patterns and results in chronic tyrosinemia in mice.

Authors:  Shuzhang Yang; Sandra M Siepka; Kimberly H Cox; Vivek Kumar; Marleen de Groot; Yogarany Chelliah; Jun Chen; Benjamin Tu; Joseph S Takahashi
Journal:  Proc Natl Acad Sci U S A       Date:  2019-10-14       Impact factor: 11.205

Review 2.  Therapeutic applications of dichloroacetate and the role of glutathione transferase zeta-1.

Authors:  Margaret O James; Stephan C Jahn; Guo Zhong; Marci G Smeltz; Zhiwei Hu; Peter W Stacpoole
Journal:  Pharmacol Ther       Date:  2016-10-19       Impact factor: 12.310

3.  Development of Flow Injection Analysis Method for the Second-Tier Estimation of Succinylacetone in Dried Blood Spot of Newborn Screening.

Authors:  Bijo Varughese; Dnyanoba Madrewar; Sunil Kumar Polipalli; Seema Kapoor
Journal:  Indian J Clin Biochem       Date:  2021-01-06

4.  Hereditary tyrosinemia type Ⅰ: newborn screening, diagnosis and treatment.

Authors:  Yue Tang; Yuanyuan Kong
Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban       Date:  2021-08-25

5.  Treatment adherence in tyrosinemia type 1 patients.

Authors:  Domingo González-Lamuño; Paula Sánchez-Pintos; Fernando Andrade; María L Couce; Luís Aldámiz-Echevarría
Journal:  Orphanet J Rare Dis       Date:  2021-06-03       Impact factor: 4.123

6.  Clinical experience with hepatorenal tyrosinemia from a single Egyptian center.

Authors:  Hanaa El-Karaksy; Hala Mohsen Abdullatif; Carolyne Morcos Ghobrial; Engy Adel Mogahed; Noha Adel Yasin; Noha Talal; Mohamed Rashed
Journal:  PLoS One       Date:  2022-05-10       Impact factor: 3.752

7.  Silent Tyrosinemia Type I Without Elevated Tyrosine or Succinylacetone Associated with Liver Cirrhosis and Hepatocellular Carcinoma.

Authors:  Patrick R Blackburn; Raymond D Hickey; Rebecca A Nace; Nasra H Giama; Daniel L Kraft; Andrew J Bordner; Roongruedee Chaiteerakij; Jennifer B McCormick; Maja Radulovic; Rondell P Graham; Michael S Torbenson; Silvia Tortorelli; C Ronald Scott; Noralane M Lindor; Dawn S Milliner; Devin Oglesbee; Wafa'a Al-Qabandi; Markus Grompe; Dimitar K Gavrilov; Mounif El-Youssef; Karl J Clark; Paldeep S Atwal; Lewis R Roberts; Eric W Klee; Stephen C Ekker
Journal:  Hum Mutat       Date:  2016-08-08       Impact factor: 4.878

Review 8.  Nuclease-Mediated Gene Therapies for Inherited Metabolic Diseases of the Liver.

Authors:  Taylor E Bryson; Caitlin M Anglin; P Hudson Bridges; Renee N Cottle
Journal:  Yale J Biol Med       Date:  2017-12-19

9.  Outcome of Tyrosinemia Type 1 in Indian Children.

Authors:  Sonal Mirani; Vishrutha Poojari; Naman S Shetty; Ira Shah
Journal:  J Clin Exp Hepatol       Date:  2020-07-11

Review 10.  Evaluation of pre-symptomatic nitisinone treatment on long-term outcomes in Tyrosinemia type 1 patients: a systematic review.

Authors:  Julia Geppert; Chris Stinton; Karoline Freeman; Hannah Fraser; Aileen Clarke; Samantha Johnson; Paul Sutcliffe; Sian Taylor-Phillips
Journal:  Orphanet J Rare Dis       Date:  2017-09-11       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.